Our results show that a reduction of glucosylceramidase protein levels and activity in fibroblasts from Gaucher disease, Parkinson’s disease with GBA mutations and non-manifesting carriers is because of a combination of decreases in GBA transcript levels and endoplasmic reticulum retention of glucosylceramidase protein. Here, GBA1 is linked to Gaucher disease.